^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pomalidomide

    i
    Other names: CC 4047, CDC 394, CC-4047 , CDC-394, CC4047, CDC394
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor
    Related drugs:
    1d
    DURGA-4: A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma. (clinicaltrials.gov)
    P3, N=508, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120
    1d
    DoMMino-1: Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=100, Recruiting, CellCentric Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • pomalidomide • inobrodib (CCS1477)
    3d
    Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. (PubMed, Sci Rep)
    This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • ARID2 (AT-Rich Interaction Domain 2) • IRF4 (Interferon regulatory factor 4)
    |
    pomalidomide • Farydak (panobinostat)
    6d
    Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma. (PubMed, Blood Neoplasia)
    Triplet regimens that include an immunomodulatory agent, proteasome inhibitor, and dexamethasone are widely used in newly diagnosed and relapsed/refractory (R/R) multiple myeloma (MM)...Additionally, we have compared these results with similar combinations with the immunomodulatory agent pomalidomide (POM). Our studies indicate that the MEZI/BTZ/DEX triplet is superior to all single agents and POM/BTZ/DEX in terms of potency of antiproliferative and proapoptotic activities, substrate degradation depth and kinetics in the presence of BTZ, and in vivo efficacy. We show that the combination of MEZI with BTZ increases cell death through disruption of multiple phases of the cell cycle and this thereby enhances the direct cytotoxic effects of the combination treatment.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    bortezomib • dexamethasone • pomalidomide • mezigdomide (CC-92480)
    15d
    DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov)
    P1/2, N=153, Recruiting, GlaxoSmithKline | Phase classification: P1 --> P1/2 | N=55 --> 153
    Phase classification • Enrollment change
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    16d
    A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • pomalidomide • Empliciti (elotuzumab)
    18d
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    18d
    Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    pomalidomide
    24d
    Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • pomalidomide • Winrevair (sotatercept-csrk)
    24d
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    29d
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=125, Recruiting, K36 Therapeutics, Inc. | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    carfilzomib • dexamethasone • pomalidomide • mezigdomide (CC-92480) • gintemetostat (KTX-1001)
    1m
    MAGNETISMM-5: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (clinicaltrials.gov)
    P3, N=944, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)